AGEN - AGENUS INC
IEX Last Trade
2.81
0.045 1.601%
Share volume: 6,034
Last Updated: Thu 26 Dec 2024 08:29:08 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$2.76
0.05
1.63%
Fundamental analysis
23%
Profitability
18%
Dept financing
25%
Liquidity
14%
Performance
30%
Performance
5 Days
1.10%
1 Month
-18.64%
3 Months
-46.81%
6 Months
-80.65%
1 Year
-83.24%
2 Year
12.24%
Key data
Stock price
$2.81
DAY RANGE
$2.69 - $2.80
52 WEEK RANGE
$0.83 - $19.69
52 WEEK CHANGE
-$83.02
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Garo H. Armen
Region: US
Website: agenusbio.com
Employees: 440
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: agenusbio.com
Employees: 440
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Agenus Inc. discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer.
Recent news